<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02492594</url>
  </required_header>
  <id_info>
    <org_study_id>VB MD-AN-007-3D</org_study_id>
    <nct_id>NCT02492594</nct_id>
  </id_info>
  <brief_title>Optimized Diagnostics for Improved Therapy Stratification in Invasive Fungal Infections</brief_title>
  <acronym>FUNGITECT</acronym>
  <official_title>Optimized Diagnostics for Improved Therapy Stratification in Invasive Fungal Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Anna Kinderkrebsforschung</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Anna Kinderkrebsforschung</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Invasive fungal infections (IFI) in immunocompromised patients pose a major challenge for&#xD;
      diagnostics designed to permit timely onset of appropriate treatment. The aim of the current&#xD;
      clinical-diagnostic studies, one in in pediatric and one in adult patients at high risk of&#xD;
      IFI, is to test newly developed diagnostic approaches to invasive fungal infections in&#xD;
      relation to established procedures. The studies will be performed in a prospective, blinded&#xD;
      fashion, and represent a work package within the FUNGITECT grant supported by the European&#xD;
      Commission. The studies will focus on analyses of blood-samples from patients with febrile&#xD;
      neutropenia during treatment of acute leukaemia and other tumour entities, and patients&#xD;
      undergoing allogeneic stem cell transplantation treated with intensive chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Samples from immunosuppressed patients with febrile neutropenia (NP - defined as fever ≥&#xD;
      38.5ºC and &lt;500 ANC) will be taken:&#xD;
&#xD;
        -  at the start of neutropenic fever&#xD;
&#xD;
        -  after 24 hours&#xD;
&#xD;
        -  after 48 hours&#xD;
&#xD;
        -  before the start of antimycotic therapy, if pertinent&#xD;
&#xD;
        -  at the end of antimycotic therapy, if pertinent&#xD;
&#xD;
      The results ot analyses by a panfungal PCR screening assay developed at our institution&#xD;
      (European patent No 1960536) and methods newly developed during the FUNGITECT project will be&#xD;
      compared with conventional methods for fungal diagnostics such as HR (High Resolution)-CT,&#xD;
      serological testing, histology and fungal culture. Additionally, genomic approaches will be&#xD;
      employed to investigate host- and pathogen-related factors of susceptibility, pathogenicity&#xD;
      and antimycotic resistance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Actual">March 31, 2019</completion_date>
  <primary_completion_date type="Actual">March 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with fungal DNAmia (as indicator of fungal infection) detected by new methodologies described in the proposal</measure>
    <time_frame>until the end of antifungal treatment (up to 6 weeks after the onset of febrile neutropenia)</time_frame>
    <description>Invasive fungal diseases will be evaluated by developing improved diagnosis: technical validation of individual assays (PCR-based, NGS, and protein-based), validation of biomarkers in clinical specimens (MoAbs, proteinaceous infection markers) and optimized for time and parallel processing of samples by establishing a robust protocol to generate reproducible results, implementation of automated or semi-automated techniques and by use of defined quality control systems.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of individual fungal pathogens during febrile neutropenia in high risk patients</measure>
    <time_frame>until the end of antifungal treatment (up to 6 weeks after the onset of febrile neutropenia)</time_frame>
    <description>The frequency of invasive fungal disease in the paediatric and adult patient cohorts as well as in each individual patient will be elucidated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of fungal pathogens resistant to commonly used antifungal agents</measure>
    <time_frame>until the end of antifungal treatment (up to 6 weeks after the onset of febrile neutropenia)</time_frame>
    <description>Progress and changes in healthcare practices provide opportunities for new and drug-resistant fungal pathogens emerging in hospital settings.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of lethal fungal infections</measure>
    <time_frame>until the end of antifungal treatment (up to 6 weeks after the onset of febrile neutropenia)</time_frame>
    <description>Evaluation of potentially life-threatening fungal infections according to EORTC criteria.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">244</enrollment>
  <condition>Systemic Mycosis</condition>
  <arm_group>
    <arm_group_label>Pediatric patients with febrile neutropenia</arm_group_label>
    <description>Peripheral blood sampling - samples from 200 pediatric patients with severe immunosuppression and neutropenic fever will be analyzed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adult patients with febrile neutropenia</arm_group_label>
    <description>Peripheral blood sampling - samples from 200 adult patients with severe immunosuppression and neutropenic fever will be analyzed</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Peripheral blood sampling</intervention_name>
    <description>Peripheral blood samples will be taken at 3-5 defined timepoints during febrile neutropenia:&#xD;
at the start of neutropenic fever&#xD;
after 24 hours&#xD;
after 48 hours&#xD;
before the start of antimycotic therapy, if pertinent&#xD;
at the end of antimycotic therapy, if pertinent</description>
    <arm_group_label>Adult patients with febrile neutropenia</arm_group_label>
    <arm_group_label>Pediatric patients with febrile neutropenia</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Material that is not analyzed immediately will be stored until end of the study.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        1. Adult Patients between 18-90 years of age with high risk of invasive fungal infections&#xD;
             (patients suffering from acute leukaemia and other tumour entities treated with&#xD;
             intensive chemotherapy with neutropenic fever&#xD;
&#xD;
          2. Pediatric patients between 0-18 years of age with high risk of invasive fungal&#xD;
             infections ((patients suffering from acute leukaemia, patients undergoing allogeneic&#xD;
             stem cell transplantation treated with intensive chemotherapy with neutropenic fever.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        INCLUSION CRITERIA&#xD;
&#xD;
        Adult study:&#xD;
&#xD;
          -  Patients between 18-90 years of age with high risk of invasive fungal infections&#xD;
&#xD;
          -  signed informed consent&#xD;
&#xD;
        Pediatric study:&#xD;
&#xD;
          -  patients between 0-18 years of age with high risk of invasive fungal infections&#xD;
&#xD;
          -  signed informed consent&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
        Adult study:&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  no consent&#xD;
&#xD;
        Pediatric study:&#xD;
&#xD;
        - no consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Lion, Prof MD PhD MSc</last_name>
    <role>Study Chair</role>
    <affiliation>St. Anna Kinderkrebsforschung</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Vienna, Department of Internal Medicine I</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Hietzing</name>
      <address>
        <city>Vienna</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanusch Krankenhaus</name>
      <address>
        <city>Vienna</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilhelminenspital</name>
      <address>
        <city>Vienna</city>
        <zip>1160</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Anna Children's Hospital</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Máxima Center for pediatric oncology</name>
      <address>
        <city>Utrecht</city>
        <zip>3508</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Saint-Petersburg Pavlov State Medical University</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Netherlands</country>
    <country>Russian Federation</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>http://www.kinderkrebsforschung.at/</url>
    <description>Link to the web page of the Children's Cancer Research Institute (St. Anna Kinderkrebsforschung), the sponsor of the study.</description>
  </link>
  <results_reference>
    <citation>Landlinger C, Preuner S, Bašková L, van Grotel M, Hartwig NG, Dworzak M, Mann G, Attarbaschi A, Kager L, Peters C, Matthes-Martin S, Lawitschka A, van den Heuvel-Eibrink MM, Lion T. Diagnosis of invasive fungal infections by a real-time panfungal PCR assay in immunocompromised pediatric patients. Leukemia. 2010 Dec;24(12):2032-8. doi: 10.1038/leu.2010.209. Epub 2010 Sep 30.</citation>
    <PMID>20882044</PMID>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>May 28, 2015</study_first_submitted>
  <study_first_submitted_qc>July 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2015</study_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Invasive Fungal Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

